AMI Asset Management Corp Sells 34,547 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

AMI Asset Management Corp lessened its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 44.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,141 shares of the company's stock after selling 34,547 shares during the period. AMI Asset Management Corp owned about 0.06% of Kiniksa Pharmaceuticals International worth $1,194,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Corebridge Financial Inc. increased its position in Kiniksa Pharmaceuticals International by 3.6% during the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after buying an additional 549 shares during the last quarter. GAMMA Investing LLC increased its position in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the last quarter. Sound View Wealth Advisors Group LLC increased its position in Kiniksa Pharmaceuticals International by 4.0% during the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after buying an additional 568 shares during the last quarter. Martingale Asset Management L P increased its position in Kiniksa Pharmaceuticals International by 1.3% during the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock worth $1,111,000 after buying an additional 640 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock worth $507,000 after buying an additional 1,002 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on KNSA shares. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. TD Cowen initiated coverage on Kiniksa Pharmaceuticals International in a research report on Monday. They issued a "buy" rating and a $60.00 target price on the stock. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 7th. Finally, Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an "overweight" rating in a research report on Thursday, September 25th. Seven analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $44.29.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 17,000 shares of the company's stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the sale, the chief accounting officer directly owned 33,041 shares in the company, valued at $1,068,876.35. This represents a 33.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Mark Ragosa sold 18,889 shares of the stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $32.89, for a total transaction of $621,259.21. Following the sale, the chief financial officer owned 27,009 shares of the company's stock, valued at approximately $888,326.01. This represents a 41.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 603,371 shares of company stock valued at $20,434,869 in the last three months. 53.48% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $38.64 on Thursday. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $39.12. The company has a market cap of $2.86 billion, a PE ratio of 966.24 and a beta of 0.16. The stock has a 50-day moving average of $34.03 and a 200-day moving average of $28.45.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.